僧帽弁逆流症に対するM-TEER(経皮的僧帽弁形成術)による弁形成術
Christos Iliadis1, Stephan Baldus2
1Faculty of Medicine and University Hospital Cologne, Department III for Internal Medicine, University of Cologne, Cologne, Germany. christos.iliadis@uk-koeln.de.
Abstract:
Mitral valve transcatheter edge-to-edge repair (M-TEER) has emerged as an alternative therapy for mitral regurgitation (MR), addressing the unmet clinical need for patients with high surgical risk. Previous large randomized controlled trials (RCTs), including EVEREST II, COAPT, and MITRA-FR, have established the safety and efficacy of M‑TEER for both etiologies of MR: primary (PMR) and secondary MR (SMR). The field of SMR treatment has been updated by the recent RCTs RESHAPE-HF2 and MATTERHORN, which have expanded the recommendations of M‑TEER in the current European guidelines. This article summarizes key evidence from pivotal trials, discusses patient selection, and presents ongoing studies in the field of M‑TEER.
関連する概念動画
Mitral Regurgitation III: Medical Management
Mitral Stenosis III: Medical Management
Mitral Regurgitation IV: Nursing Management
Mitral Regurgitation I: Introduction
Mitral Valve Prolapse II: Assessment and Management
Mitral Valve Prolapse I: Introduction


